Concerns About Eye Toxicity Could Limit GSK’s Myeloma Drug Potential

US FDA Flags Safety Ahead Of Meeting

 
• By Andrew McConaghie
  
GSK_HQ
2020 marks GSK's return to the oncology field, including the highly competitive multiple myeloma market

More from Business

More from Scrip